Virtual Nature Versus Guided Imagery for Anxiety and Well-Being in Hospitalized Older Adults

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorSemmelweis University

About this trial

Long hospital stays can be difficult for older adults. Being confined to a ward, with limited mobility and little access to the outdoors, may contribute to anxiety, low mood, and reduced well-being. Contact with nature is known to support relaxation and emotional recovery, but hospitalized patients often cannot go outside.

This study compares two ways of bringing a nature experience to patients who are staying in hospital. In the first approach, participants wear a virtual reality headset and watch 360-degree videos filmed in real natural settings near Budapest: a meadow, a stream, and a mountain. The nature scene reaches them through their eyes and ears. In the second approach, participants listen to a short recorded audio guide and picture the same three nature scenes in their own minds, with their eyes closed. Here the nature scene is created by their own imagination.

Both approaches use exactly the same nature themes. The only difference is how the experience reaches the person: from the outside through the senses, or from the inside through imagination. The study asks whether these two routes have different effects, and whether they can be told apart by measuring heart rate variability, which reflects how the body's automatic nervous system responds.

Participants are adults aged 65 or older who have been in hospital for at least two weeks. After joining the study, each participant is first observed for two weeks while receiving only their usual hospital care. This period serves as their own comparison. They are then assigned by chance to one of the two approaches and take part in three sessions over two weeks. Questionnaires and brief cognitive tests are completed at three points: when joining, before the sessions begin, and after the sessions end.

The main question is whether anxiety symptoms decrease more during the session period than during the preceding period of usual care. The study also looks at mood, attention and memory, well-being, and resilience.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Aged 65 years or older

Receiving inpatient hospital care, with at least two weeks of hospitalisation at the time of enrolment

Montreal Cognitive Assessment (Hungarian version) score of 18 or above, with education correction

Physically able to safely wear a head-mounted virtual reality display

Disqualifiers

Epilepsy with recurrent seizures, or photosensitivity

Neurological condition associated with increased risk during virtual reality use, including Meniere's disease and significant carotid stenosis

Active psychosis, hallucinations, or severe depression with psychotic features

Open wound or skin lesion on the face, chronic neck pain, or spinal condition preventing safe use of the head-mounted display

Trial design

Design model

Parallel

Treatments tested in this trial

  • Immersive virtual reality nature exposure

    Device

    Three sessions of 360-degree nature video viewed through a head-mounted display, delivered over two weeks. Videos were produced by the research team from a fixed tripod perspective at three locations near Budapest, corresponding to the motifs of meadow, stream, and mountain. They contain no narration or added music, only the natural soundscape of the location, and the viewpoint changes every five minutes. Exposure length ranges from 8 to 20 minutes according to participant tolerance. Sessions are conducted at the bedside under supervision, with the device used offline.

  • Guided imagery

    Behavioral

    Three sessions of guided imagery delivered over two weeks. Participants listen through headphones, with eyes closed, to a standardized five-minute audio recording that begins with a brief breathing relaxation followed by the motif text. The motifs are identical to those presented in the virtual reality arm and are drawn from the motif repertoire of Katathym Imaginative Psychotherapy. After each session, participants give a free verbal account of their experience.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Immersive virtual reality nature exposureExperimental treatment 1 intervention
Group B: Guided imageryActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Heart rate variability during intervention sessions relative to resting and cognitive-load recordings (RMSSD)

Root mean square of successive differences (RMSSD, ln-transformed) recorded during intervention sessions and compared within each participant with their own resting recording (20-minute recording during the usual care period, five-minute window analysed) and cognitive-load recordings (T0 and T1). RMSSD is computed from a five-minute artifact-free window in all contexts; higher values indicate greater parasympathetic activity. Recordings with more than 5 percent corrected beats are excluded from the primary analysis. Recordings are made with an optical photoplethysmographic armband sensor; the first five participants were recorded with a chest-strap ECG sensor in all contexts. The between-arm comparison of session RMSSD is a secondary, exploratory analysis.

Time frame
Baseline through Week 4 (resting recording during the usual care period; cognitive load at baseline and Week 2; intervention sessions from Week 2 through Week 4)
2

Primary Outcome 1 - HADS-A

Anxiety symptoms measured with the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21; lower scores indicate less anxiety. The primary comparison is the change during the intervention period (T1 to T2) relative to the change during the preceding usual care observation period (T0 to T1), with each participant serving as their own control (self-controlled, non-randomised contrast, both arms pooled). The randomised between-arm comparison of T2 scores adjusted for T1 scores is a secondary analysis. Analyses use linear mixed models.

Time frame
Baseline, Week 2, and Week 4.

Secondary outcomes

1

Change in depressive symptoms (HADS-D)

Depressive symptoms measured with the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scores range from 0 to 21; lower scores indicate fewer depressive symptoms.

Time frame
Baseline, Week 2, and Week 4
2

Change in depressive symptoms (GDS-15)

Depressive symptoms measured with the 15-item Geriatric Depression Scale (GDS-15). Scores range from 0 to 15; higher scores indicate more depressive symptoms.

Time frame
Baseline, Week 2, and Week 4
3

Change in global cognitive performance (MoCA)

Global cognitive performance measured with the Montreal Cognitive Assessment, Hungarian version. Scores range from 0 to 30 with education correction; higher scores indicate better cognitive performance. Three parallel versions (8.1, 8.2, 8.3) are administered in fixed order across the three assessment points to reduce practice effects.

Time frame
Baseline, Week 2, and Week 4
4

Change in memory index (MoCA-MIS)

Memory Index Score derived from the delayed recall section of the Montreal Cognitive Assessment, weighting free recall, category-cued recall, and multiple-choice recall. Scores range from 0 to 15; higher scores indicate better memory performance.

Time frame
Baseline, Week 2, and Week 4

Other outcomes

1

Affective state before intervention sessions (Emotion Thermometers)

Affective state assessed with the Emotion Thermometers, comprising five visual analogue dimensions (distress, anxiety, depression, anger, and need for help). Each dimension is rated from 0 to 10; higher scores indicate greater distress. The instrument is administered at each assessment point (baseline, Week 2, Week 4) and immediately before each intervention session. It is not administered after the sessions, in order to minimise participant burden and to preserve the period immediately following the session, during which participants in the guided imagery arm give their verbal account. The measure characterises the affective state at the start of each assessment and session day and its trajectory across the four weeks of participation, rather than acute within-session change.

Time frame
Baseline, Week 2, Week 2 through Week 4, and Week 4
2

Immersive tendency (ITQ-10)

Dispositional tendency to become involved and absorbed in an experience, measured with the 10-item Hungarian version of the Immersive Tendencies Questionnaire. Higher scores indicate a greater tendency towards immersion. The questionnaire is administered once, before randomisation, in both arms, and is treated as a trait-level moderator variable rather than a mediator. Only the total score is used; the subscales are not analysed separately because two items of the attention focus subscale refer to current alertness and physical condition, which in hospitalised older adults primarily reflect current illness burden.

Time frame
Baseline
3

Virtual reality sickness symptoms (VRSQ)

Symptoms associated with virtual reality use, measured with the Virtual Reality Sickness Questionnaire, comprising nine items grouped into an oculomotor and a disorientation component; higher scores indicate more severe symptoms. The questionnaire is administered in the virtual reality arm only, after the first session. It is used to monitor tolerability rather than as an efficacy outcome. Tolerability in both arms is additionally monitored at every session through structured recording of adverse events by the facilitator.

Time frame
Week 2

Sponsors and contacts

Click on the lead sponsor to view all of their trials.